Free Trial

Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Upgraded by B. Riley

Kymera Therapeutics logo with Medical background

Key Points

  • B. Riley has initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with a "buy" rating and a price target of $60.00, indicating a potential upside of 35% from the current stock price.
  • Multiple research firms have rated Kymera Therapeutics positively, with a consensus rating of "Buy" and an average price target of $59.11.
  • Kymera Therapeutics reported significantly increased revenue in its latest earnings report, with a 114.6% year-over-year growth, and beat earnings estimates by posting ($0.82) EPS compared to the consensus estimate of ($0.92).
  • MarketBeat previews top five stocks to own in September.

B. Riley upgraded shares of Kymera Therapeutics (NASDAQ:KYMR - Free Report) to a strong-buy rating in a research report report published on Wednesday, Marketbeat.com reports. B. Riley currently has $60.00 price target on the stock. B. Riley also issued estimates for Kymera Therapeutics' Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.71) EPS, FY2026 earnings at ($4.03) EPS, FY2027 earnings at ($4.56) EPS and FY2028 earnings at ($3.80) EPS.

A number of other equities analysts have also issued reports on the company. HC Wainwright restated a "buy" rating and issued a $60.00 target price (up previously from $54.00) on shares of Kymera Therapeutics in a research note on Thursday, June 26th. JPMorgan Chase & Co. increased their price target on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 3rd. Bank of America raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target on the stock in a research report on Monday, June 2nd. BTIG Research reaffirmed a "buy" rating and set a $59.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Finally, Stifel Nicolaus started coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $55.00 price target on the stock. Two research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $59.11.

Check Out Our Latest Report on KYMR

Kymera Therapeutics Stock Performance

KYMR stock traded down $0.84 during midday trading on Wednesday, reaching $42.91. The stock had a trading volume of 58,005 shares, compared to its average volume of 746,074. The stock has a market cap of $2.79 billion, a PE ratio of -13.94 and a beta of 2.18. The firm has a fifty day simple moving average of $43.58 and a two-hundred day simple moving average of $36.55. Kymera Therapeutics has a 52-week low of $19.44 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The company had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The firm's quarterly revenue was up 114.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.69) EPS. On average, sell-side analysts predict that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, Director Elena Ridloff sold 12,000 shares of Kymera Therapeutics stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total value of $553,200.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bvf Partners L. P/Il acquired 317,167 shares of the business's stock in a transaction on Monday, June 30th. The shares were purchased at an average price of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the purchase, the director owned 2,798,795 shares in the company, valued at $123,146,980. This represents a 12.78% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 48,349 shares of company stock worth $2,334,301 over the last quarter. Company insiders own 16.01% of the company's stock.

Institutional Investors Weigh In On Kymera Therapeutics

Several large investors have recently bought and sold shares of the company. KBC Group NV increased its stake in Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after buying an additional 328 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Kymera Therapeutics by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company's stock worth $110,000 after buying an additional 343 shares in the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after purchasing an additional 406 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares during the last quarter. Finally, Comerica Bank boosted its holdings in shares of Kymera Therapeutics by 3.6% during the 1st quarter. Comerica Bank now owns 21,374 shares of the company's stock worth $585,000 after purchasing an additional 743 shares during the last quarter.

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Featured Stories

Analyst Recommendations for Kymera Therapeutics (NASDAQ:KYMR)

Should You Invest $1,000 in Kymera Therapeutics Right Now?

Before you consider Kymera Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.

While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines